• AdvanCell closed an oversubscribed, upsized Series D round of USD 315 million to scale its targeted alpha radiopharmaceutical business.
• The clinical-stage company is developing Lead-212-based therapies, led by ADVC001, a PSMA-targeted treatment for metastatic prostate cancer in Phase 2.
• Sanofi Ventures participated alongside other existing investors; Ally Bridge Group led the financing with Alpha Wave as co-lead.
• Proceeds target Phase 3 preparation for ADVC001, expanded isotope supply, accelerated pipeline development, increased U.S. manufacturing capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi Ventures published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.